- Home
- TBPH vs SANA Comparison
TBPH vs SANA Comparison
Compare TBPH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBPH | SANA |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 793.1M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBPH | SANA |
|---|---|---|
| Price | $16.66 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $18.40 | $7.80 |
| AVG Volume (30 Days) | 320.5K | ★ 3.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.82 | $2.58 |
| 52 Week High | $21.03 | $6.55 |
Technical Indicators
Market Signals| Indicator | TBPH | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 53.18 |
| Support Level | $16.07 | $3.01 |
| Resistance Level | $17.21 | $3.41 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 79.70 | 64.05 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.